https://www.selleckchem.com/pr....oducts/poziotinib-hm
tivity was 75.0% and specificity was 56.7%, respectively. Subgroup analysis showed that the 28-day mortality in the patients with N/LPR ≥ 15.48 (n = 21) was significantly higher than those with N/LPR 15.48 (n = 29; 71.4% vs. 17.2%, χ = 14.901, P 0.01); and the 28-day mortality in the patients with NLR ≥ 10.65 (n = 28) was also significantly higher than those with NLR 10.65 (n = 22; 53.6% vs. 22.7%, χ = 4.884, P 0.05). The results were consistent with Kaplan-Meier survival curve analysis. Peripheral blood
Curtir
Comentario
Compartilhar
